IBB:NSD-iShares Nasdaq Biotechnology Index Fund

ETF | Health | NASDAQ Global Market

Last Closing Price

USD 101.93


0.00 (0.00)%

Market Cap

USD 8.06B



Average Target Price

Average Analyst Rating


STA Verdict



The investment seeks to track the investment results of the NASDAQ Biotechnology Index, which contains securities of NASDAQ? listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals and that also meet other eligibility criteria determined by Nasdaq, Inc. The fund generally invests at least 90% of its assets in securities of the index and in depositary receipts representing securities of the index. It may invest the remainder of its assets in certain futures, options and swap contracts, cash and cash equivalents. It is non-diversified.

Inception Date: 05/02/2001

Primary Benchmark: NASDAQ Biotechnology TR USD

Primary Index: MSCI ACWI NR USD

Gross Expense Ratio: 0.47%

Management Expense Ratio: 0.47 %

Unadjusted Closing Price

Adjusted Closing Price



Top Sectors


Top Regions


Share Volume

Relative Performance (Total Returns)

Relative Returns (From:    To: 2018-12-15 )

Largest Industry Peers for Health

Symbol Name Mer Price(Change) Market Cap
PSCH Invesco S&P SmallCap Health Ca.. 0.29 %


USD 1.05B
BBH VanEck Vectors Biotech ETF 0.35 %


USD 0.40B
PPH VanEck Vectors Pharmaceutical .. 0.35 %


USD 0.26B
PTH Invesco DWA Healthcare Momentu.. 0.60 %


USD 0.23B
BTEC Principal Healthcare Innovator.. 0.42 %


USD 0.05B
CNCR Loncar Cancer Immunotherapy ET.. 0.79 %


USD 0.04B
FTXH First Trust Nasdaq Pharmaceuti.. 0.60 %


USD 4.06M
GNRX VanEck Vectors Generic Drugs E.. 0.57 %


USD 3.28M
SLIM The Obesity ETF 0.50 %


USD 3.26M
LNGR Global X Longevity Thematic ET.. 0.52 %



ETFs Containing IBB

HAC.A:CA Horizons Seasonal Rotatio.. 5.37 % 3.14 %


CAD 9.26M

Market Performance

  Market Performance vs.
Industry/Classification (Health)
Market Performance vs. Exchange (NASDAQ Global Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Capital Gain -4.53% 55% F 62% D-
Dividend Return 0.18% 40% F 2% F
Total Return -4.36% 55% F 59% F
Trailing 12 Months  
Capital Gain -4.38% 45% F 61% D-
Dividend Return 0.29% 22% F 4% F
Total Return -4.09% 36% F 58% F
Trailing 5 Years  
Capital Gain 41.90% 60% D- 64% D
Dividend Return 1.19% 40% F 3% F
Total Return 43.10% 60% D- 60% D-
Average Annual (5 Year Horizon)  
Capital Gain 9.06% 55% F 56% F
Dividend Return 9.24% 55% F 53% F
Total Return 0.18% 27% F 5% F
Risk Return Profile  
Volatility (Standard Deviation) 22.01% 18% F 59% F
Risk Adjusted Return 41.98% 45% F 54% F
Market Capitalization 8.53B 100% A+ 93% A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.